Conferences - Seminars
Resveratrol in the management of obesity-related fatty liver disease: a randomized, double-blind, placebo-controlled clinical trial
By Véronique CHACHAY
Accredited Practising Dietitian, MSc Nutrition and Dietetics, PhD candidate
The University of Queensland Diamantina Institute -Metabolic medicine group
Research wing, Princess Alexandra Hospital, Ipswich Road
Brisbane, Qld 4102, Australia
Primary outcome: Peripheral insulin resistance, (euglycemic-hyperinsulinemic clamp).
Secondary outcomes: Hepatic triglycerides content and abdominal adipose tissue topography (magnetic resonance spectroscopy and imaging); plasma adiponectin (total and high molecular-weight); oxidative-stress and antioxidant capacity (isoprostanes, TAC, GPX, FRAP, SOD); inflammatory and liver biochemistry.
Conclusion: Despite demonstrated prevention of NAFLD in animal models, nutraceutical trans-resveratrol at this dosage, over 8 weeks, did not demonstrate apparent clinical benefit in patients with well established NAFLD.
Organization Kristina Schoonjans and Johan Auwerx
Contact Johan Auwerx
Accessibility General public